Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SB Avandia, Takeda/Lilly Actos Antidiabetics Set For Advisory Cmte. Review

Executive Summary

SmithKline Beecham's Avandia and Takeda/Lilly's Actos have been scheduled for review by an FDA advisory committee one month after the agency plans to discuss the safety of the first "glitazone" insulin sensitizer Rezulin.

You may also be interested in...



Glucophage AEs Not Comparable To Rezulin Liver Deaths - FDA Consultant

The risk of lactic acidosis associated with Bristol-Myers Squibb's Glucophage should not be compared to liver toxicities associated with Rezulin because the Glucophage side effects can be more easily managed through education, FDA consultant Saul Genuth, MD, Case Western Reserve University, told FDA's Endocrinologic & Metabolic Drugs Advisory Committee.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel